Anti-androgen therapy is commonly used to treat patients with advanced prostate cancer at stages where the disease has spread to the bones. However, new research has found that anti-androgen treatment can actually facilitate prostate cancer cells to adapt and grow in the bone tumor microenvironment model developed by biomedical scientists.
Researchers have unveiled important new insights into how hormones known as androgens act on our cells – and the discovery could boost efforts to develop better treatments for prostate, ovarian and breast cancers.
This study builds on decades of work showing that the protein IL-24 attacks cancer broadly, and is the first to deliver the protein using T cells. This approach is in contrast to CAR-T cells, which are built to recognize proteins on the surface of cancer cells and haven’t been successful against solid tumors. Mice with prostate cancer experienced shrinkage of the original tumor as well as distant metastases following treatment with IL-24 T cells.
A urine test could have avoided one third of unnecessary prostate cancer biopsies while failing to detect only a small number of cancers, according to a validation study that included more than 1,500 patients.
A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research.
Researchers find that CRY-1, a regulator of circadian rhythms, promotes tumor progression by altering DNA repair.
Drinking several cups of coffee every day may be linked to a lower risk of developing prostate cancer, suggests a pooled data analysis of the available evidence.
Improving imaging processes will lead to more successful treatments and help reduce morbidity in men with the disease.
In a study to examine a Mediterranean diet in relation to prostate cancer progression in men on active surveillance, researchers found that men with localized prostate cancer who reported a baseline dietary pattern that more closely follows the key principles of a Mediterranean-style diet fared better over the course of their disease.
Researchers are investigating whether inflammation in the body, a side effect of ADT, contributes to these symptoms in prostate cancer patients. They pinpoint a specific inflammation marker that is associated with increased fatigue in this group of patients.
Clinical trials underway are testing whether drugs that target the androgen receptor — successful in controlling prostate cancer — could also work against the coronavirus.
Researchers have identified a gene signature in localized prostate cancer that predicts the cancer’s odds of spreading and its response to a common treatment for advanced disease.
The development and validation of a staging system for non-metastatic prostate cancer could help doctors and patients assess treatment options, as well as improve clinical trials.
A new intraoperative imaging technique, Cerenkov luminescence imaging (CLI), can accurately assess surgical margins during radical prostatectomy, according to a first-in-human research. The feasibility study showed that 68Ga-PSMA CLI can image the entire excised prostate specimen’s surface to detect prostate cancer tissue at the resection margin.
Researchers reported that the SUCLA2 gene is frequently involved in the deletion of the tumor suppressor gene RB1 in advanced prostate cancer. RB1 deletion makes cells resistant to hormone therapy but SUCLA2 deletion induces a metabolic weakness. The study showed that thymoquinone selectively killed SUCLA2-deficient prostate cancer cells in vitro and in vivo. The findings highlight a vulnerability of advanced prostate cancer cells that can be targeted by drugs.
An increased awareness on a molecular level of what mechanisms prostate cancer cells use to become mobile and start spreading may in the long run provide new opportunities for treatment of aggressive prostate cancer. This according to a new study by researchers at Umeå University, Sweden, in collaboration with researchers in Uppsala and Tokyo.
A new type of test that uses complex sugars to detect prostate cancer earlier and with greater accuracy.
A five-year follow-up study of more than 2,000 US men who received prostate cancer treatment is creating a road map for future patients regarding long-term bowel, bladder and sexual function in order to clarify expectations and enable men to make informed choices about care.
Artificial intelligence (AI) technology has successfully found features in pathology images from human cancer patients, without annotation, that could be understood by human doctors. Further, the AI identified features relevant to cancer prognosis that were not previously noted by pathologists, leading to a higher accuracy of prostate cancer recurrence compared to pathologist-based diagnosis.
A prescription of short-term exercise for patients with advanced prostate cancer could help to reduce the side-effects of hormone therapy, according to new research. The trial aimed to reduce the adverse side-effects of hormone therapy such as weight gain and an increased risk of heart problems. The results show that a three month programme of aerobic and resistance training intervention prevented adverse changes in cardiopulmonary fitness and fatigue
A study suggests a new approach, or, possibly two new approaches against prostate cancer bone metastases: While targeted therapies and anti-cancer immunotherapies have not been especially successful against primary prostate cancers, the study suggests that both these approaches may be effective against the bone metastases that grow from primary prostate cancers, and, in fact, the type of bone metastasis may dictate which targeted therapies and immunotherapies work best.
Some men with advanced prostate cancer who have exhausted all other treatment options could live for two years or more on immunotherapy, a major clinical trial has shown. Researchers found that a small proportion of men were ‘super responders’ and were alive and well even after the trial had ended despite having had a very poor prognosis before treatment.
A new home urine test for prostate cancer could revolutionize diagnosis — according to new research. As well as diagnosing aggressive prostate cancer, the test predicts whether patients will require treatment up to five years earlier than standard clinical methods. It also means that men don’t have to come into the clinic to provide a urine sample — or have to undergo an uncomfortable rectal examination.
A research team identified 87 patients who were part of the Intermountain INSPIRE Registry and had developed prostate cancer. These patients were also tested for plasma levels of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are two common omega-3 fatty acids.